Skip to main content

Table 5 Relation between delta BNP and different parameters

From: B-type natriuretic peptide (BNP) in HCV-positive Egyptian patients: the impact of HCV eradication on plasma BNP levels

 

N

delta in BNP

Test of sig.

p

Median (min.–max.)

Mean ± SD.

Sex

 Male

26

1.7(− 21–35.9)

4.2 ± 14.1

U = 764.0

0.620

 Female

63

1.9(− 147.1–180)

2.5 ± 43.7

BMI (pre)

 18.5–24.9

22

− 1.2(− 45.4–10.4)

− 3.5 ± 14.2

U = 585.0

0.150

 25.0–29.9

67

3.2(− 147.1–180.0)

5.1 ± 42.3

Normal liver

 No

28

− 5.4(− 147.1–11.9)

− 12.8 ± 39.1

U = 492.0*

0.001*

 Yes

61

2.8(− 45.4–180)

10.2 ± 34.7

Type drug

 SOF + DAC

63

1.9(− 45.4–180)

7.4 ± 34.6

U = 776.0

0.698

 SOF + DAC + RIB

26

1.5(− 147.1–33.9)

− 7.7 ± 42.6

FIB4 (pre)

 < 1.45

43

3.9(− 5–180)

16.1 ± 38.5

H = 18.428*

< 0.001*

 1.45–3.25

42

− 2.9(− 45.4–20.7)

− 3.7 ± 13.1

 > 3.25

4

− 67.6(− 147.1–11.9)

− 67.6 ± 91.8

APRI (pre)

 < 0.5

46

3.9(− 9.5–180)

12.6 ± 37.5

H = 15.741*

< 0.001*

 0.5–1.5

39

− 1(− 21–35.9)

1.8 ± 12.8

  > 1.5

4

− 96.3(− 147.1–− 45.4)

− 96.3 ± 58.7

  1. U Mann Whitney test, H H for Kruskal Wallis test, p p value for association between different categories
  2. BMI body mass index, SOF sofosbuvir, DAC daclatasvir, RIB ribavirin, APRI score aspartate aminotransferase-to-platelet ratio index score
  3. *Statistically significant at p ≤ 0.05